AU2021268033A1 - APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof - Google Patents

APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof Download PDF

Info

Publication number
AU2021268033A1
AU2021268033A1 AU2021268033A AU2021268033A AU2021268033A1 AU 2021268033 A1 AU2021268033 A1 AU 2021268033A1 AU 2021268033 A AU2021268033 A AU 2021268033A AU 2021268033 A AU2021268033 A AU 2021268033A AU 2021268033 A1 AU2021268033 A1 AU 2021268033A1
Authority
AU
Australia
Prior art keywords
seq
immunomodulatory protein
amino acid
set forth
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021268033A
Other languages
English (en)
Inventor
Daniel William DEMONTE
Stacey Dillon
Lawrence Evans
Joseph L. Kuijper
Stanford L. PENG
Mark Rixon
Ryan SWANSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpine Immune Sciences Inc
Original Assignee
Alpine Immune Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpine Immune Sciences Inc filed Critical Alpine Immune Sciences Inc
Publication of AU2021268033A1 publication Critical patent/AU2021268033A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021268033A 2020-05-08 2021-05-07 APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof Pending AU2021268033A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063022373P 2020-05-08 2020-05-08
US63/022,373 2020-05-08
US202063034361P 2020-06-03 2020-06-03
US63/034,361 2020-06-03
US202063080643P 2020-09-18 2020-09-18
US63/080,643 2020-09-18
PCT/US2021/031432 WO2021226553A2 (en) 2020-05-08 2021-05-07 April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof

Publications (1)

Publication Number Publication Date
AU2021268033A1 true AU2021268033A1 (en) 2022-12-15

Family

ID=76270049

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2021268033A Pending AU2021268033A1 (en) 2020-05-08 2021-05-07 APRIL and BAFF inhibitory immunomodulatory proteins with and without a T cell inhibitory protein and methods of use thereof
AU2021267276A Active AU2021267276B2 (en) 2020-05-08 2021-05-07 APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
AU2025200430A Pending AU2025200430A1 (en) 2020-05-08 2025-01-22 APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021267276A Active AU2021267276B2 (en) 2020-05-08 2021-05-07 APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
AU2025200430A Pending AU2025200430A1 (en) 2020-05-08 2025-01-22 APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof

Country Status (19)

Country Link
US (6) US20230241168A1 (https=)
EP (2) EP4146683B1 (https=)
JP (3) JP7748393B2 (https=)
KR (2) KR20230029621A (https=)
CN (5) CN117736297A (https=)
AU (3) AU2021268033A1 (https=)
BR (2) BR112022022433A2 (https=)
CA (2) CA3178882A1 (https=)
CL (1) CL2022003104A1 (https=)
CO (1) CO2022017780A2 (https=)
DK (1) DK4146683T3 (https=)
FI (1) FI4146683T3 (https=)
HR (1) HRP20260229T1 (https=)
IL (2) IL297981A (https=)
MX (2) MX2022013999A (https=)
PE (1) PE20230494A1 (https=)
RS (1) RS67815B1 (https=)
TW (1) TW202208414A (https=)
WO (2) WO2021226551A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
KR20220034742A (ko) * 2019-12-24 2022-03-18 레메젠 코, 리미티드 Taci-fc 융합 단백질 및 그 용도
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
JP2024514077A (ja) * 2021-03-31 2024-03-28 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 切断したｔａｃｉポリペプチド及びその融合タンパク質並びに使用
KR20240019124A (ko) * 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
AU2022327178A1 (en) * 2021-08-11 2024-03-28 Akso Biopharmaceutical, Inc. METHODS OF REDUCING PRODUCTION OF IgA, IgM AND/OR IgG USING sBCMA VARIANTS AND FC FUSION PROTEINS THEREOF
JP2024538452A (ja) * 2021-11-17 2024-10-21 オーリニア・ファーマシューティカルズ・インコーポレイテッド Ｂ細胞活性化因子（ｂａｆｆ）－増殖誘導リガンド（ａｐｒｉｌ）二重阻害剤
IL317055A (en) * 2022-06-08 2025-01-01 Remegen Co Ltd METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN
WO2024044721A1 (en) * 2022-08-25 2024-02-29 University Of Washington Injectable recombinant protein-based hydrogels for therapeutic delivery
JP2025532251A (ja) * 2022-09-30 2025-09-29 レメゲン シーオー．，エルティーディー． ＴＡＣＩ－Ｆｃ融合タンパク質を用いた膜性腎症の治療方法
WO2024077018A2 (en) * 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein
KR20250116728A (ko) * 2022-12-05 2025-08-01 알렉시온 파마슈티칼스, 인코포레이티드 Baff, april, 및 신생아 fc 수용체의 다기능적 억제를 위한 taci-fc 융합 단백질
EP4527375A1 (en) * 2022-12-07 2025-03-26 RemeGen Co., Ltd. Taci-fc fusion protein liquid pharmaceutical preparation
WO2025007943A1 (zh) * 2023-07-06 2025-01-09 荣昌生物制药(烟台)股份有限公司 用taci-fc融合蛋白治疗anca相关性血管炎的方法
WO2025240392A1 (en) * 2024-05-13 2025-11-20 Paragon Therapeutics, Inc. Fusion proteins
WO2026008004A1 (zh) * 2024-07-04 2026-01-08 荣昌生物制药(烟台)股份有限公司 用TACI-Fc融合蛋白治疗抗磷脂综合征的方法

Family Cites Families (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5443964A (en) 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
DK0584266T3 (da) 1991-05-06 2003-12-29 Us Gov Health & Human Serv Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
JP4418965B2 (ja) 1994-09-23 2010-02-24 タップイミューン・インコーポレイテッド 内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法
JP3907698B2 (ja) 1994-10-03 2007-04-18 アメリカ合衆国 抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
ES2248823T5 (es) 1996-10-25 2011-11-03 Human Genome Sciences, Inc. Neutroquina alfa.
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
GB9801930D0 (en) 1998-01-29 1998-03-25 Univ London Mutant herpes simplex viruses and uses thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
GB2337755B (en) 1998-05-29 2003-10-29 Secr Defence Virus vaccine
DK2272859T3 (en) 1998-08-07 2015-01-19 Univ Washington Immunological herpes simplex virus antigens and methods for their use
US20060067933A1 (en) 1999-01-07 2006-03-30 Gross Jane A Soluble receptor BR43x2 and methods of using
DE60043626D1 (de) 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
US7833529B1 (en) * 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
US7329728B1 (en) 1999-10-25 2008-02-12 The Scripps Research Institute Ligand activated transcriptional regulator proteins
CA2396793A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US20040013674A1 (en) 2001-04-27 2004-01-22 Christine Ambrose Taci as an anti-tumor agent
JP2004513876A (ja) 2000-04-27 2004-05-13 バイオジェン　インコーポレーテッド 抗−腫瘍剤としてのｔａｃｉ
EP1746106A3 (en) 2000-04-27 2007-03-14 Biogen Idec MA Inc. Use of TACI as an anti-tumor agent
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
CA2413160A1 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2411828A1 (en) 2000-06-23 2002-01-03 Maxygen, Inc. Novel co-stimulatory molecules
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
JP2004537290A (ja) 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
BRPI0209933B8 (pt) 2001-05-24 2021-05-25 Zymogenetics Inc proteína de fusão, e, molécula de ácido nucleico
BR0211614A (pt) 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
EP1456347A4 (en) 2001-11-16 2006-08-02 Human Genome Sciences Inc IMMUNE SPECIFIC TO BLYS BINDING ANTIBODIES
US7247615B2 (en) 2001-11-30 2007-07-24 United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptide agonists of prostate-specific antigen and uses therefor
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
CN1692127A (zh) 2002-07-25 2005-11-02 健泰科生物技术公司 Taci抗体及其用途
EP1558278B1 (en) 2002-10-11 2009-09-02 ZymoGenetics, Inc. Production of homotrimeric fusion proteins
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
AU2004285455A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for BAFF antagonists
KR100956913B1 (ko) 2003-12-19 2010-05-11 제넨테크, 인크. 치료제로서 유용한 일가 항체 단편
KR100891620B1 (ko) 2004-04-13 2009-04-02 에프. 호프만-라 로슈 아게 항-ｐ-셀렉틴 항체
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
CA2585927A1 (en) 2004-11-04 2006-05-18 Genentech, Inc. Polypeptides that bind baff and/or april
WO2006060314A2 (en) 2004-12-01 2006-06-08 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
BRPI0518994A2 (pt) 2004-12-31 2008-12-02 Biogen Idec Inc anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1922079A2 (en) 2005-08-09 2008-05-21 ZymoGenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
AU2006278229B2 (en) 2005-08-09 2011-10-27 Ares Trading S.A. Methods for treating B-cell malignancies using TACI-Ig fusion molecule
WO2007019618A1 (en) 2005-08-12 2007-02-22 Garvan Institute Of Medical Research Phrophylactic and/or therapeutic method for treatment of autoimmune disease
JP2007103345A (ja) 2005-09-07 2007-04-19 Toyota Motor Corp チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法
ES2415890T3 (es) 2005-09-09 2013-07-29 Zymogenetics, Inc. Procedimiento de preparación de proteínas triméricas
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
EA015860B1 (ru) 2005-10-13 2011-12-30 Хьюман Дженом Сайенсиз, Инк. Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
US8202698B2 (en) 2005-11-08 2012-06-19 Biogen Idec Ma Inc. Methods of evaluating BAFF
JP2009537563A (ja) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
BRPI0714495B8 (pt) 2006-07-21 2021-05-25 California Inst Of Techn lentivírus deficiente para replicação recombinante pseudotipado
JP2010501622A (ja) 2006-08-28 2010-01-21 アレス トレーディング ソシエテ アノニム Ｆｃ−融合タンパク質の精製法
EA017733B1 (ru) 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
DK2061803T4 (da) 2006-08-28 2022-12-05 Ares Trading Sa Fremgangsmåde til oprensning af fc-holdige proteiner
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
CA2674213A1 (en) 2007-01-26 2008-07-31 Merck Serono S.A. Purification of fc-taci fusion proteins using the oilbody technology
JP5426531B2 (ja) 2007-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド 自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ
SG182191A1 (en) 2007-06-13 2012-07-30 Zymogenetics Inc Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
CN101323643B (zh) 2007-06-15 2010-12-01 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
EP2170946A2 (en) 2007-07-13 2010-04-07 The Johns Hopkins University B7-dc variants
EP2200631A1 (en) 2007-10-16 2010-06-30 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
CA2701221A1 (en) 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
WO2009062960A1 (en) 2007-11-12 2009-05-22 Ares Trading S.A. Formulations for taci-immunoglobulin fusion proteins
JP2011503036A (ja) 2007-11-12 2011-01-27 アレス トレーディング ソシエテ アノニム 再発性多発性硬化症治療のためのｔａｃｉ−免疫グロブリン融合タンパク質
WO2009062916A1 (en) 2007-11-12 2009-05-22 Ares Trading S.A. Taci-immunoglobulin fusion proteins for treatment of optic neuritis
RS56844B1 (sr) 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
AU2009241442B2 (en) 2008-05-01 2014-11-27 Zymogenetics, Inc. Levels of BLyS/ APRIL heterotrimers in serum and use in diagnostic methods
EP2540740B1 (en) 2008-06-17 2014-09-10 Apogenix GmbH Multimeric TNF receptors
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
EP2435477A1 (en) 2009-05-28 2012-04-04 Glaxo Group Limited Antigen-binding proteins
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
CN101851278B (zh) 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
US20110311548A1 (en) 2010-06-18 2011-12-22 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
US20130295672A1 (en) 2010-09-10 2013-11-07 Consejo Superior De Investigaciones Científicas Stem cell culture media and methods
CN102085368B (zh) 2011-01-19 2013-06-12 烟台荣昌生物工程有限公司 优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
EP2686345B1 (en) 2011-03-16 2018-04-25 Amgen Inc. Fc variants
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
RS55609B1 (sr) 2011-04-13 2017-06-30 Bristol Myers Squibb Co Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
WO2012149364A1 (en) 2011-04-28 2012-11-01 Diamond Don J Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
WO2013041029A1 (en) * 2011-09-23 2013-03-28 Igenimed Pharmaceuticals Inc. Novel soluble ctla4 variants
TWI476001B (zh) 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
CN102585016B (zh) * 2012-03-06 2014-06-04 江苏健德生物药业有限公司 一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
PT2831095T (pt) 2012-03-30 2019-01-30 Immune Design Corp Partículas de vectores lentivirais com melhor eficácia de transdução de células que expressam dc-sign
MX2014014951A (es) 2012-06-06 2015-03-13 Oncomed Pharm Inc Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
CN103232542B (zh) * 2013-02-01 2015-05-13 殷勇 一种双靶标嵌合蛋白
EP3744728A1 (en) 2013-02-12 2020-12-02 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
ES2870802T3 (es) 2013-02-12 2021-10-27 Bristol Myers Squibb Co Métodos de replegado de proteínas a elevado pH
HK1219740A1 (zh) 2013-03-15 2017-04-13 Biogen Ma Inc. 使用抗αVβ5抗体治疗和预防急性肾损伤
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
US10562954B2 (en) * 2014-05-12 2020-02-18 Shanghai Kanda Biotechnology Co., Ltd. Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
WO2015181343A2 (en) 2014-05-30 2015-12-03 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for pd-l1
EP3169352A1 (en) 2014-07-15 2017-05-24 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
WO2016023001A1 (en) 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
TWI833684B (zh) 2015-06-25 2024-03-01 美商生物細胞基因治療有限公司 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
EP3322801A1 (en) 2015-07-15 2018-05-23 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
US10954301B2 (en) * 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
ES2898329T3 (es) 2016-01-12 2022-03-07 Oncotracker Inc Métodos mejorados para supervisar el estado inmunitario de un sujeto
EP4706777A2 (en) 2016-04-15 2026-03-11 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Immunomodulatory proteins ICOS ligand variants and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US20200326339A1 (en) 2016-05-16 2020-10-15 James Richard BERENSON Improved methods for monitoring immune status of a subject
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
CN110088127A (zh) 2016-07-28 2019-08-02 高山免疫科学股份有限公司 Cd155变体免疫调节蛋白及其用途
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
CA3040296A1 (en) 2016-10-20 2018-04-26 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
PT3596116T (pt) 2017-03-16 2023-12-04 Alpine Immune Sciences Inc Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3642243A4 (en) 2017-06-20 2021-04-28 Dana-Farber Cancer Institute, Inc. METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION
CN111655280B (zh) 2017-09-01 2025-01-14 达纳-法伯癌症研究所股份有限公司 用于治疗癌症的bcma和taci抗原特异的免疫原性肽
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SMT202600062T1 (it) 2017-10-18 2026-03-09 Alpine Immune Sciences Inc Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati
GB201720426D0 (en) 2017-12-07 2018-01-24 Hummingbird Bioscience Pte Ltd CD47 and BCMA antigen-binding molecules
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
US20210238295A1 (en) 2018-04-26 2021-08-05 University Of Virginia Patent Foundation Compositions and methods for treating abdominal aortic aneurysm
CN110522908A (zh) 2018-05-25 2019-12-03 荣昌生物制药（烟台）有限公司 TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
WO2020028572A2 (en) 2018-08-01 2020-02-06 Unum Therapeutics Inc. ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
WO2020047329A1 (en) 2018-08-29 2020-03-05 Shattuck Labs, Inc. Chimeric proteins comprising extracellular domains and uses thereof
AU2019345151B2 (en) 2018-09-19 2025-04-17 Alpine Immune Sciences, Inc. Methods and uses of variant CD80 fusion proteins and related constructs
WO2020097403A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020113141A2 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
EP4438054A3 (en) 2019-04-17 2025-01-08 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
CN114728040A (zh) 2019-06-14 2022-07-08 科优基因公司 新型白介素-2变体及其双功能融合分子
EP4056232A4 (en) 2019-09-13 2023-09-13 Kyowa Kirin Co., Ltd. DCR3 VARIANT
AU2020401160B2 (en) 2019-12-10 2024-11-14 Remegen Co., Ltd. Pharmaceutical TACI-Fc fusion protein formulation
KR20220034742A (ko) 2019-12-24 2022-03-18 레메젠 코, 리미티드 Taci-fc 융합 단백질 및 그 용도
JP7748393B2 (ja) 2020-05-08 2025-10-02 アルパイン イミューン サイエンシズ インコーポレイテッド Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
AU2021285813A1 (en) 2020-06-02 2023-02-02 Ares Trading S.A. Methods related to the treatment of IGA nephropathy
KR20240019124A (ko) 2021-05-07 2024-02-14 알파인 이뮨 사이언시즈, 인코포레이티드 Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
US20240002468A1 (en) 2021-08-10 2024-01-04 Remegen Co., Ltd. Method for treating iga nephropathy with taci-fc fusion protein
AU2022358137B2 (en) 2021-09-30 2026-02-12 Remegen Co., Ltd. Method for treating sjogren’s syndrome using taci-fc fusion protein
IL317055A (en) 2022-06-08 2025-01-01 Remegen Co Ltd METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN
WO2024077018A2 (en) 2022-10-04 2024-04-11 Alpine Immune Sciences, Inc. Methods and uses of taci-fc fusion immunomodulatory protein

Also Published As

Publication number Publication date
KR20230029621A (ko) 2023-03-03
RS67815B1 (sr) 2026-03-31
MX2022013998A (es) 2023-02-16
JP2023525033A (ja) 2023-06-14
BR112022022524A2 (pt) 2022-12-13
CN117736297A (zh) 2024-03-22
BR112022022433A2 (pt) 2022-12-13
WO2021226553A3 (en) 2022-04-28
US20250019412A1 (en) 2025-01-16
US11274140B2 (en) 2022-03-15
KR20230029622A (ko) 2023-03-03
CN116903727A (zh) 2023-10-20
JP7748393B2 (ja) 2025-10-02
CL2022003104A1 (es) 2023-07-14
WO2021226553A2 (en) 2021-11-11
CO2022017780A2 (es) 2023-03-17
EP4146684A2 (en) 2023-03-15
EP4146683A1 (en) 2023-03-15
AU2021267276B2 (en) 2024-10-24
US20230241168A1 (en) 2023-08-03
PE20230494A1 (es) 2023-03-23
MX2022013999A (es) 2023-02-16
CN116194467A (zh) 2023-05-30
CN119258195A (zh) 2025-01-07
US12202882B2 (en) 2025-01-21
HRP20260229T1 (hr) 2026-03-27
IL297981A (en) 2023-01-01
WO2021226551A1 (en) 2021-11-11
AU2025200430A1 (en) 2025-02-20
JP2025134866A (ja) 2025-09-17
US20240218045A1 (en) 2024-07-04
CA3178885A1 (en) 2021-11-11
CN115812077A (zh) 2023-03-17
IL297980A (en) 2023-01-01
AU2021267276A1 (en) 2022-12-15
US12304943B2 (en) 2025-05-20
US20250019413A1 (en) 2025-01-16
DK4146683T3 (da) 2026-02-09
US20210363223A1 (en) 2021-11-25
FI4146683T3 (fi) 2026-03-13
CA3178882A1 (en) 2021-11-11
US20240400643A1 (en) 2024-12-05
TW202208414A (zh) 2022-03-01
EP4146683B1 (en) 2026-01-28
US20210388054A1 (en) 2021-12-16
JP2023525032A (ja) 2023-06-14

Similar Documents

Publication Publication Date Title
US12304943B2 (en) April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
US20240279310A1 (en) Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
EP4598557A2 (en) Mutated taci-fc fusion proteins for use in the treatment of autoantibody-mediated diseases
US12612447B2 (en) April and BAFF inhibitory immunomodulatory proteins and methods of use thereof
HK40102763A (zh) 具有和不具有t细胞抑制蛋白的april和baff抑制性免疫调节蛋白及其使用方法
CN117915937A (zh) 使用TACI-Fc融合免疫调节蛋白的给药和治疗方法
HK40109407A (zh) April和baff抑制性免疫调节蛋白及其使用方法